Announcements
Clinical and Experimental Obstetrics & Gynecology (CEOG) is published by IMR Press from Volume 47 Issue 1 (2020). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.
Original Research
Mid-luteal phase injection of subcutaneous leuprolide acetate improves live delivered pregnancy and implantation rates in younger women undergoing in vitro fertilization-embryo transfer (IVF-ET)
Show Less
1
Cooper Medical School of Rowan University, Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology & Infertility, Camden, NJ
2
Cooper Institute For Reproductive Hormonal Disorders, P.C., Mt. Laurel, NJ (USA)
Clin. Exp. Obstet. Gynecol. 2016, 43(2), 173–174;
https://doi.org/10.12891/ceog3227.2016
Published: 10 April 2016
Abstract
Purpose: To determine if a single injection of one-mg leuprolide acetate three days after embryo transfer (ET) in younger women causes an increase in pregnancy rates, and if so, is it associated with a higher initial serum hCG level? Materials and Methods: A prospective study was initiated where women aged ≤ 35 years were offered the option of taking the leuprolide or not. Results: Though a significant difference was not found, there was a trend for higher live delivered pregnancy rates in those taking the leuprolide supplement (47.8%) vs. those not taking it (38.6%). There was no difference in the first serum beta hCG level. Conclusions: The trends is interesting enough to continue with a higher powered study.
Keywords
GnRH agonist
Leuprolide acetate
Embryo implantation rate
Beta hCG levels